BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 15247129)

  • 21. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.
    Colombo N; Formelli F; Cantù MG; Parma G; Gasco M; Argusti A; Santinelli A; Montironi R; Cavadini E; Baglietto L; Guerrieri-Gonzaga A; Viale G; Decensi A
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1914-9. PubMed ID: 17035399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
    Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
    Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic markers for early detection of ovarian cancer.
    Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
    Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
    Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
    Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
    Xu Y; Shen Z; Wiper DW; Wu M; Morton RE; Elson P; Kennedy AW; Belinson J; Markman M; Casey G
    JAMA; 1998 Aug; 280(8):719-23. PubMed ID: 9728644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
    Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
    Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
    Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
    Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lysophosphatidic acid in ovarian cancer patients].
    Sedlákova I; Vávrová J; Tosner J; Hanousek L
    Ceska Gynekol; 2006 Jul; 71(4):312-7. PubMed ID: 16956044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
    Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
    Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry.
    Scherer M; Schmitz G; Liebisch G
    Clin Chem; 2009 Jun; 55(6):1218-22. PubMed ID: 19325012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of plasma lysophosphatidic acid levels in the differential diagnosis of ovarian cancer.
    Zhang YJ; Cao LY; Fu ZZ; Wang YJ; Wang GX; Gu T
    J Cancer Res Ther; 2015; 11(2):375-80. PubMed ID: 26148603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LC-MS/MS-analysis of sphingosine-1-phosphate and related compounds in plasma samples.
    Schmidt H; Schmidt R; Geisslinger G
    Prostaglandins Other Lipid Mediat; 2006 Dec; 81(3-4):162-70. PubMed ID: 17085324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A clean-up technology for the simultaneous determination of lysophosphatidic acid and sphingosine-1-phosphate by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using a phosphate-capture molecule, Phos-tag.
    Morishige J; Urikura M; Takagi H; Hirano K; Koike T; Tanaka T; Satouchi K
    Rapid Commun Mass Spectrom; 2010 Apr; 24(7):1075-84. PubMed ID: 20213695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells.
    Shen Z; Belinson J; Morton RE; Xu Y; Xu Y
    Gynecol Oncol; 1998 Dec; 71(3):364-8. PubMed ID: 9887232
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer.
    Eichbaum MH; Weiss LM; Bruckner T; Schneeweiss A; Sinn HP; Gebauer G; Fersis N; Kussmaul J; Sohn C
    Med Sci Monit; 2009 Apr; 15(4):CR156-63. PubMed ID: 19333199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
    Akçay T; Dinçer Y; Alademir Z; Aydinli K; Arvas M; Demirkiran F; Kösebay D
    Eur J Obstet Gynecol Reprod Biol; 2005 Mar; 119(1):108-13. PubMed ID: 15734094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
    Resnick KE; Alder H; Hagan JP; Richardson DL; Croce CM; Cohn DE
    Gynecol Oncol; 2009 Jan; 112(1):55-9. PubMed ID: 18954897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case control study of glycoprotein status in ovarian carcinoma.
    Aranganathan S; Senthil K; Nalini N
    Clin Biochem; 2005 Jun; 38(6):535-9. PubMed ID: 15885233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.